Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Short Duration Daptomycin vs Conventional Therapy in cSSSI
NCT00426933Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Primary completion
- Sep 2007
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of daptomycin in Skin and Skin Structure Infection (SSSI), sponsored by Merck & Co.. Started Jan 2007; status: completed.
02
Drugs
daptomycin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00426933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426933.